{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:01:44Z","timestamp":1789650104456,"version":"4.0.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12072-021-10137-2","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T07:02:56Z","timestamp":1614409376000},"page":"290-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Chronic hepatitis B: the demise of the \u2018inactive carrier\u2019 phase"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-3847","authenticated-orcid":false,"given":"Apostolos","family":"Koffas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upkar S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T. F.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"10137_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370\u2013398","journal-title":"J Hepatol"},{"key":"10137_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jhep.2015.03.013","volume":"63","author":"C-L Chen","year":"2015","unstructured":"Chen C-L, Yang J-Y, Lin S-F, et al. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol 2015;63:354\u2013363","journal-title":"J Hepatol"},{"key":"10137_CR3","doi-asserted-by":"publisher","first-page":"30009","DOI":"10.2807\/1560-7917.ES.2015.20.35.30009","volume":"20","author":"N Coppola","year":"2015","unstructured":"Coppola N, Alessio L, Gualdieri L, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill 2015;20:30009","journal-title":"Euro Surveill"},{"key":"10137_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00103-016-2333-8","volume":"59","author":"A Hampel","year":"2016","unstructured":"Hampel A, Solbach P, Cornberg M, Schmidt RE, Behrens GM, Jablonka A. Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016;59:578\u2013583","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10137_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212\u20132219","journal-title":"Vaccine"},{"key":"10137_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546\u20131555","journal-title":"Lancet"},{"key":"10137_CR7","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095\u20132128","journal-title":"Lancet"},{"issue":"1","key":"10137_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1\u201398","journal-title":"Hepatol Int"},{"key":"10137_CR9","unstructured":"WHO. World Health Organization factsheet: hepatitis B 2017. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/"},{"key":"10137_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coviro.2018.03.006","volume":"30","author":"GE Dolman","year":"2018","unstructured":"Dolman GE, Koffas A, Mason WS, Kennedy PT. Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol 2018;30:39\u201347","journal-title":"Curr Opin Virol"},{"issue":"2","key":"10137_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7861\/clinmedicine.15-2-191","volume":"15","author":"US Gill","year":"2015","unstructured":"Gill US, Kennedy PTF. New insights in the management of chronic hepatitis B. Clin Med (Lond) 2015;15(2):191\u2013196","journal-title":"Clin Med (Lond)"},{"key":"10137_CR12","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016;64:S4\u2013S16","journal-title":"J Hepatol"},{"key":"10137_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bpg.2017.04.013","volume":"31","author":"ZS Valaydon","year":"2017","unstructured":"Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. Best Pract Res Clin Gastroenterol 2017;31:257\u2013264","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10137_CR14","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","volume":"64","author":"J Lucifora","year":"2016","unstructured":"Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA\u2014the holy grail to hepatitis B cure. J Hepatol 2016;64:S41\u2013S48","journal-title":"J Hepatol"},{"key":"10137_CR15","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 2017;9:E75","journal-title":"Viruses"},{"issue":"1","key":"10137_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41426-018-0145-7","volume":"7","author":"MA Budzinska","year":"2018","unstructured":"Budzinska MA, Shackel NA, Urban S, Tu T. Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. Emerg Microbes Infect 2018;7(1):142","journal-title":"Emerg Microbes Infect"},{"key":"10137_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/v5051261","volume":"5","author":"DY Gong","year":"2013","unstructured":"Gong DY, Chen EQ, Huang FJ, Leng XH, Cheng X, Tang H. Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. Viruses 2013;5:1261\u20131271","journal-title":"Viruses"},{"key":"10137_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","volume":"151","author":"WS Mason","year":"2016","unstructured":"Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 2016;151:986\u2013998","journal-title":"Gastroenterology"},{"key":"10137_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000360947","volume":"57","author":"A Kramvis","year":"2014","unstructured":"Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology 2014;57:141\u2013150","journal-title":"Intervirology"},{"key":"10137_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3748\/wjg.14.1112","volume":"14","author":"J You","year":"2008","unstructured":"You J, Sriplung H, Geater A, et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol 2008;14:1112\u20131119","journal-title":"World J Gastroenterol"},{"key":"10137_CR21","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1128\/JVI.79.5.3016-3027.2005","volume":"79","author":"M Chen","year":"2005","unstructured":"Chen M, S\u00e4llberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016\u20133027","journal-title":"J Virol"},{"key":"10137_CR22","doi-asserted-by":"publisher","first-page":"e36349","DOI":"10.1371\/journal.pone.0036349","volume":"7","author":"S Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m S, Larsson SB, Hannoun C, Lindh M. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load\u2013down-regulated transcription of PgRNA has limited impact. PLoS ONE 2012;7:e36349","journal-title":"PLoS ONE"},{"issue":"8","key":"10137_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1086\/521864","volume":"45","author":"R Iorio","year":"2007","unstructured":"Iorio R, Giannattasio A, Cirillo F, D\u2019Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45(8):943\u2013949","journal-title":"Clin Infect Dis"},{"key":"10137_CR24","first-page":"369","volume":"92","author":"WHO","year":"2017","unstructured":"WHO. Hepatitis B vaccines: WHO position paper\u2014July 2017. Wkly Epidemiol Rec 2017;92:369\u2013392","journal-title":"Wkly Epidemiol Rec"},{"key":"10137_CR25","unstructured":"WHO (2020) Hepatitis B. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed Dec 2020"},{"key":"10137_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10137_CR27","doi-asserted-by":"publisher","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","volume":"177","author":"A Koffas","year":"2020","unstructured":"Koffas A et al. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783.","journal-title":"Antiviral Res"},{"key":"10137_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","volume":"143","author":"PT Kennedy","year":"2012","unstructured":"Kennedy PT, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012;143:637\u2013645","journal-title":"Gastroenterology"},{"issue":"5","key":"10137_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","volume":"134","author":"M Kumar","year":"2008","unstructured":"Kumar M, Sarin SK, Hissar S, et al. Virological and histological features of chronic hepatitis b virus infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134(5):1376\u20131384","journal-title":"Gastroenterology"},{"issue":"2","key":"10137_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.gastro.2009.05.058","volume":"137","author":"M Kumar","year":"2009","unstructured":"Kumar M, Sarin SK. Hepatitis B virus immune-tolerant patients: need to differentiate patients with or without liver disease. Gastroenterology 2009;137(2):742\u2013743","journal-title":"Gastroenterology"},{"issue":"5","key":"10137_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/hep.21585","volume":"45","author":"CL Lin","year":"2007","unstructured":"Lin CL, Liao LY, Liu CJ, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45(5):1193\u20131198","journal-title":"Hepatology"},{"key":"10137_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2893.2011.01450.x","volume":"19","author":"YC Chen","year":"2012","unstructured":"Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat 2012;19:138\u2013146","journal-title":"J Viral Hepat"},{"key":"10137_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jhep.2011.11.030","volume":"57","author":"GV Papatheodoridis","year":"2012","unstructured":"Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012;57:196\u2013202","journal-title":"J Hepatol"},{"issue":"5","key":"10137_CR34","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142(5):1140\u20131149","journal-title":"Gastroenterology"},{"issue":"2","key":"10137_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017;66(2):398\u2013411","journal-title":"J Hepatol"},{"issue":"5","key":"10137_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2012.12.006","volume":"58","author":"J Liu","year":"2013","unstructured":"Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58(5):853\u2013860","journal-title":"J Hepatol"},{"issue":"1","key":"10137_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/liv.12735","volume":"35","author":"M Martinot-Peignoux","year":"2015","unstructured":"Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int 2015;35(1):82\u201390","journal-title":"Liver Int"},{"issue":"1","key":"10137_CR38","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","volume":"10","author":"JH Kim","year":"2020","unstructured":"Kim JH, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep 2020;10(1):1835","journal-title":"Sci Rep"},{"issue":"20","key":"10137_CR39","first-page":"30492","volume":"S0016\u20135085","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Gill US, Hong M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic HBV infection. Gastroenterology 2020;S0016\u20135085(20):30492\u201330493","journal-title":"Gastroenterology"},{"key":"10137_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12072-007-9002-9","volume":"1","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007;1:311\u2013315","journal-title":"Hepatol Int"},{"issue":"4","key":"10137_CR41","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1053\/j.gastro.2009.01.011","volume":"136","author":"M Kumar","year":"2009","unstructured":"Kumar M, Chauhan R, Gupta N, Hissar SS, Sakhuja P, Sarin SK. Spontaneous increase in ALT levels in asymptomatic chronic hepatitis B virus infected patients. Gastroenterology 2009;136(4):1272\u20131280","journal-title":"Gastroenterology"},{"issue":"1","key":"10137_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/gut.2007.128496","volume":"57","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Olivari N, Pasino M, D\u2019Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57(1):84\u201390","journal-title":"Gut"},{"issue":"5","key":"10137_CR43","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1053\/j.gastro.2007.08.039","volume":"133","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007;133(5):1458\u20131465","journal-title":"Gastroenterology"},{"key":"10137_CR44","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/0016-5085(87)90614-7","volume":"92","author":"NC Tassopoulos","year":"1987","unstructured":"Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987;92:1844\u20131850","journal-title":"Gastroenterology"},{"issue":"6","key":"10137_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1440-1746.2007.05243.x","volume":"23","author":"M Kumar","year":"2008","unstructured":"Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol 2008;23(6):883\u2013887","journal-title":"J Gastroenterol Hepatol"},{"key":"10137_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","volume":"36","author":"M Martinot-Peignoux","year":"2002","unstructured":"Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543\u2013546","journal-title":"J Hepatol"},{"issue":"3","key":"10137_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7861\/clinmedicine.18-3-212","volume":"18","author":"A Koffas","year":"2018","unstructured":"Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond) 2018;18(3):212\u2013218","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"10137_CR48","doi-asserted-by":"publisher","first-page":"635.e9","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology 2019;156(3):635.e9\u2013646.e9","journal-title":"Gastroenterology"},{"issue":"3","key":"10137_CR49","first-page":"227","volume":"4","author":"K Zhou","year":"2019","unstructured":"Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses lancet. Gastroenterol Hepatol 2019;4(3):227\u2013238","journal-title":"Gastroenterol Hepatol"},{"key":"10137_CR50","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen MF, Wong DK, Fung J, et al. HBsAg sero-clearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192\u20131199","journal-title":"Gastroenterology"},{"key":"10137_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","volume":"118","author":"JH Kao","year":"2000","unstructured":"Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554\u2013559","journal-title":"Gastroenterology"},{"key":"10137_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/jhep.2003.50036","volume":"37","author":"H Sumi","year":"2003","unstructured":"Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19\u201326","journal-title":"Hepatology"},{"issue":"2","key":"10137_CR53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/gutjnl-2014-306977","volume":"64","author":"TC Tseng","year":"2015","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64(2):292\u2013302","journal-title":"Gut"},{"issue":"3","key":"10137_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MOG.0b013e328324f478","volume":"25","author":"B Degertekin","year":"2009","unstructured":"Degertekin B, Lok ASF. Update on viral hepatitis: 2008. Curr Opin Gastroenterol 2009;25(3):180\u2013185","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"10137_CR55","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1053\/j.gastro.2008.09.049","volume":"135","author":"M Kumar","year":"2008","unstructured":"Kumar M, Sarin SK. Liver biopsy in chronic hepatitis B virus infected patients with normal ALT. Reply. Gastroenterology 2008;135(5):1802\u20131803","journal-title":"Gastroenterology"},{"issue":"6","key":"10137_CR56","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/hep.22878","volume":"49","author":"DI Tai","year":"2009","unstructured":"Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009;49(6):1859\u20131867","journal-title":"Hepatology"},{"issue":"5","key":"10137_CR57","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, Risk Evaluation of Viral Load Elevation and Associated Liver Disease\/Cancer in HBV (REVEAL-HBV) Study Group, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138(5):1747\u20131754","journal-title":"Gastroenterology"},{"key":"10137_CR58","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","volume":"32","author":"UH Iloeje","year":"2012","unstructured":"Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012;32:1333\u20131341","journal-title":"Liver Int"},{"key":"10137_CR59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441\u2013450","journal-title":"Hepatology"},{"key":"10137_CR60","volume-title":"Stigma, Discrimination and Hepatitis B: A Review of Current Research (ARCSHS Monograph Series No. 93)","author":"J Ellard","year":"2013","unstructured":"Ellard J, Wallace J. Stigma, Discrimination and Hepatitis B: A Review of Current Research (ARCSHS Monograph Series No. 93). Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University; 2013"},{"issue":"1","key":"10137_CR61","first-page":"16","volume":"1","author":"PW Corrigan","year":"2002","unstructured":"Corrigan PW, Watson AC. Understanding the impact of stigma on people with mental illness. World Psychiatry 2002;1(1):16\u201320","journal-title":"World Psychiatry"},{"key":"10137_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10620-013-2942-0","volume":"59","author":"V Vaughn-Sandler","year":"2014","unstructured":"Vaughn-Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of perceived stigma among patients with cirrhosis. Dig Dis Sci 2014;59:681\u2013686","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10137_CR63","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/liv.13189","volume":"36","author":"K Liu","year":"2016","unstructured":"Liu K. Hepatitis B infection in China: the stigma behind the stigmata. Liver Int 2016;36(11):1582\u20131584","journal-title":"Liver Int"},{"key":"10137_CR64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2893.2011.01462.x","volume":"19","author":"SJ Cotler","year":"2012","unstructured":"Cotler SJ, Cotler S, Xie H, et al. Characterizing hepatitis B stigma in Chinese immigrants. J Viral Hepat 2012;19:147\u2013152","journal-title":"J Viral Hepat"},{"key":"10137_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/21645515.2015.1069932","volume":"12","author":"L Yu","year":"2016","unstructured":"Yu L, Wang J, Zhu D, Leng A, Wangen KR. Hepatitis B related knowledge and vaccination in association with discrimination against Hepatitis B in rural China. Hum Vaccin Immunother 2016;12:70\u201376","journal-title":"Hum Vaccin Immunother"},{"key":"10137_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/10810730.2012.688449","volume":"18","author":"L Na","year":"2013","unstructured":"Na L, Na B. A revolutionary road: an analysis of persons living with hepatitis B in China. J Health Commun 2013;18:71\u201391","journal-title":"J Health Commun"},{"key":"10137_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.12688\/wellcomeopenres.14273.1","volume":"3","author":"J Mokaya","year":"2018","unstructured":"Mokaya J, McNaughton AL, Burbridge L. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection\u2014a systematic review. Version 2. Wellcome Open Res 2018;3:29","journal-title":"Wellcome Open Res"},{"key":"10137_CR68","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0140-6736(16)31144-8","volume":"388","author":"T Lancet","year":"2016","unstructured":"Lancet T. Towards elimination of viral hepatitis by 2030. Lancet 2016;388:308","journal-title":"Lancet"},{"issue":"4","key":"10137_CR69","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","volume":"66","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 2017;66(4):1296\u20131313","journal-title":"Hepatology"},{"key":"10137_CR70","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","volume":"78","author":"GJ Webster","year":"2004","unstructured":"Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707\u20135719","journal-title":"J Virol"},{"key":"10137_CR71","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215\u20134225","journal-title":"J Virol"},{"key":"10137_CR72","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1038\/emi.2013.14","volume":"2","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Blum HE, Thimme R. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect 2013;2:e15","journal-title":"Emerg Microbes Infect"},{"key":"10137_CR73","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.4049\/jimmunol.1501362","volume":"195","author":"Z Fang","year":"2015","unstructured":"Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK\/IL-6\/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol 2015;195:4873\u20134883","journal-title":"J Immunol"},{"key":"10137_CR74","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/apt.15226","volume":"49","author":"S Pal","year":"2019","unstructured":"Pal S, Nandi M, Dey D, et al. Myeloid derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther 2019;49:1346\u20131359","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10137_CR75","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","volume":"72","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Salimzadeh L, Gill US, et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol 2020;72(1):34\u201344","journal-title":"J Hepatol"},{"issue":"10","key":"10137_CR76","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest 2018;128(10):4588\u20134603","journal-title":"J Clin Invest"},{"issue":"10","key":"10137_CR77","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virusspecific B cells in chronic hepatitis B infection. J Clin Invest 2018;128(10):4573\u20134587","journal-title":"J Clin Invest"},{"key":"10137_CR78","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325\u20131332","journal-title":"Gut"},{"key":"10137_CR79","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","volume":"18","author":"AS Alawad","year":"2020","unstructured":"Alawad AS, Auh S, Suarez D, et al. Durability of spontaneous and treatment-related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol 2020;18:700\u2013709","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10137_CR80","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/cid\/cix353","volume":"65","author":"H Chi","year":"2017","unstructured":"Chi H, Wong D, Peng J, et al. Durability of response after hepatitis B surface antigen seroclearance during nucleos(t)ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients: results after treatment cessation. Clin Infect Dis 2017;65:680\u2013683","journal-title":"Clin Infect Dis"},{"issue":"514\u2013516","key":"10137_CR81","first-page":"e2","volume":"18","author":"Y Wu","year":"2020","unstructured":"Wu Y, Liu Y, Lu J, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance. Clin Gastroenterol Hepatol 2020;18(514\u2013516):e2","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10137_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","volume":"68","author":"TC Yip","year":"2017","unstructured":"Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol 2017;68:63\u201372","journal-title":"J Hepatol"},{"issue":"3","key":"10137_CR83","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1053\/gast.2002.31887","volume":"122","author":"GKK Lau","year":"2002","unstructured":"Lau GKK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122(3):614\u2013624","journal-title":"Gastroenterology"},{"key":"10137_CR84","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","volume":"48","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013;48:13\u201321","journal-title":"J Gastroenterol"},{"issue":"3","key":"10137_CR85","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.31030","volume":"71","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Lok ASF, Terrault NA, Zoulim Z, the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL-AASLD HBV treatment endpoints conference. Hepatology 2020;71(3):1070\u20131092","journal-title":"Hepatology"},{"key":"10137_CR86","unstructured":"Consolidated Guidelines on the Use of\u00a0Antiretroviral\u00a0Drugs\u00a0for\u00a0Treating\u00a0and\u00a0Preventing\u00a0HIV Infection: Recommendations for a Public Health Approach (2016) World Health Organization, Geneva. https:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en. Accessed 2 Dec 2019"},{"key":"10137_CR87","unstructured":"(2018) Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. World Health Organization, Geneva. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf. Accessed 2 Dec 2019"},{"issue":"1","key":"10137_CR88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep.26934","volume":"60","author":"M Toy","year":"2014","unstructured":"Toy M, Salomon JA, Jiang H, et al. Population health impact and cost effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. Hepatology 2014;60(1):46\u201355","journal-title":"Hepatology"},{"key":"10137_CR89","unstructured":"Appendix A Population health impact and cost-effectiveness of chronic hepatitis B diagnosis, care, and treatment in the United States. A National Strategy for the elimination of hepatitis B and C phase two report. Authors: National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C. Editors: Brian L. Strom and Gillian J. Buckley. Washington (DC): National Academies Press (US); 2017 Mar 28"},{"key":"10137_CR90","first-page":"1","volume":"140","author":"M Kumar","year":"2014","unstructured":"Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080\u2014gaps, challenges and targets. Indian J Med Res 2014;140:1\u20134","journal-title":"Indian J Med Res"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10137-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10137-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10137-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T01:29:19Z","timestamp":1666747759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10137-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10137"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10137-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This\u00a0article\u00a0does not contain any studies with\u00a0human\u00a0or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}